Real-world outcomes of patients with retinal diseases treated with intravitreal anti-vascular endothelial growth factor (VEGF) therapies are often suboptimal when compared to the results demonstrated in pinnacle clinical studies. The discrepancies in outcomes have in part been attributed to patients receiving fewer than the recommended number of anti-VEGF injections, as well as patients discontinuing therapy due to treatment burden associated with frequent dosing schedules. New imaging techniques that allow for better monitoring of therapy response, along with the refinement of treatment protocols that extend the interval between treatment dosing, have the potential to reduce treatment burden while providing optimal visual outcomes. In this activity, experts in the field will provide guidance on the management of age-related macular degeneration (nAMD). Topics covered include utilizing recent advances in imaging to monitor treatment response in patients with retinal diseases, identification of baseline factors that help predict anti-VEGF therapy outcomes, and evaluation of anti-VEGF treatment outcomes in clinical practice. Furthermore, challenging real-world cases will be presented, allowing for incorporation of the content into clinical practice.
This activity is part of Real World Retina, a 4-part webinar series. Other activities from this series available on RetinaCME include: Focus on Diabetic Retinopathy (DR), Focus on Diabetic Macular Edema (DME), and Focus on Retinal Vein Occlusion (RVO).